Equine Influenza Study Guide

Overview and Clinical Importance

Equine influenza (EI) is one of the most economically significant and highly contagious respiratory diseases affecting horses worldwide. Caused by Influenza A virus subtypes H3N8 (the H7N7 subtype is considered extinct since no isolation since late 1970s), this disease is characterized by rapid spread, high morbidity (approaching 100% in naive populations), and low mortality. EI remains endemic in most countries except New Zealand and Iceland, which are considered disease-free.

Understanding equine influenza is essential for the NAVLE because it represents a high-yield topic that integrates virology, pathophysiology, clinical medicine, and preventive medicine concepts. Questions frequently focus on clinical recognition, differentiation from other respiratory pathogens, appropriate diagnostic testing, and vaccination protocols.

Etiology

Viral Classification

Equine influenza virus belongs to the family Orthomyxoviridae, genus Alphainfluenzavirus. It is an enveloped, negative-sense, single-stranded RNA virus with a segmented genome (8 segments). Two key surface glycoproteins determine subtype classification:

• Hemagglutinin (HA): Mediates viral attachment to host cell sialic acid receptors
• Neuraminidase (NA): Facilitates release of progeny virions from infected cells

Historical and Current Subtypes

H3N8 Lineage Evolution

The H3N8 subtype has undergone significant antigenic drift since its emergence, diverging in the late 1980s into distinct lineages:

Epidemiology

Transmission

Primary route: Inhalation of aerosolized respiratory secretions from coughing horses. Viral particles can travel up to 150 feet (approximately 45 meters) and potentially up to 1-2 km under favorable conditions.

Secondary routes: Fomite transmission via contaminated equipment (buckets, tack, brushes), clothing, hands, and shared water sources. The virus remains viable on surfaces for 2-3 days.

Key Epidemiologic Parameters

Risk Factors

• Young horses (1-5 years): More severe clinical signs; higher susceptibility
• Show/race horses: Frequent travel and congregation at events increases exposure
• Unvaccinated or poorly vaccinated horses: Most outbreaks occur in horses with unknown or lapsed vaccination
• Winter months: Greater incidence November-March (similar to EHV and strangles)
• Donkeys: Higher mortality rates compared to horses

Pathogenesis

Mechanism of Infection

Step 1 - Viral Entry: After inhalation, the viral hemagglutinin (HA) binds to sialic acid receptors (Neu5Gc2-3Gal moiety) on respiratory epithelial cells. The neuraminidase (NA) destroys mucous glycoproteins to facilitate cell access.

Step 2 - Replication: Viral replication occurs rapidly within ciliated epithelial cells of the upper and lower respiratory tract (nasal passages, trachea, bronchi, bronchioles).

Step 3 - Epithelial Destruction: Infected cells undergo apoptosis and necrosis, causing destruction of the tracheal and bronchial epithelium with complete loss of cilia. This results in loss of mucociliary clearance.

Step 4 - Regeneration: Respiratory epithelium takes approximately 21 days (3 weeks) to fully regenerate. During this period, horses are highly susceptible to secondary bacterial infections.

Gross and Histopathology

Clinical Signs

Clinical signs develop 3-5 days after exposure and begin abruptly. Uncomplicated cases typically last less than 3 days, though cough may persist for several weeks. Clinical severity varies with age, immune status, and previous exposure.

Primary Clinical Features

Complications (Less Common)

• Secondary bacterial pneumonia: Usually Streptococcus equi var. zooepidemicus; most common cause of death
• Pleuropneumonia: Severe complication requiring aggressive treatment
• Chronic bronchitis: May result from premature return to exercise
• Distal limb edema: Secondary to vasculitis; infrequent
• Myocarditis/Myositis: Rare but reported complications

Diagnosis

Clinical Diagnosis

A presumptive clinical diagnosis can be made based on: rapid-spreading respiratory infection in a group of horses characterized by rapid onset, high fever, depression, and prominent cough. However, definitive diagnosis requires laboratory confirmation as clinical signs are similar to EHV-1, EHV-4, and other respiratory pathogens.

Diagnostic Testing Methods

Differential Diagnosis

Treatment

Treatment for uncomplicated equine influenza is primarily supportive and symptomatic. There are no approved antiviral treatments for EI in horses. The goal is to minimize secondary complications and allow adequate time for respiratory epithelium regeneration.

Treatment Protocol

Prognosis

• Uncomplicated cases: Excellent; full recovery in 2-3 weeks
• Complicated cases: May require up to 6 months for complete recovery
• Mortality: Rare in horses with proper care; higher in donkeys, foals, and debilitated animals

Prevention and Control

Vaccination Protocols

Vaccination is the cornerstone of EI prevention. The AAEP (American Association of Equine Practitioners) classifies equine influenza vaccination as a core vaccination for most horses.

Available Vaccine Types

AAEP Vaccination Guidelines

WOAH (World Organisation for Animal Health) Recommendation: Vaccines should contain representative strains from BOTH Florida Clade 1 AND Clade 2 unless using modified-live vaccine.

Biosecurity and Outbreak Management

• Quarantine new arrivals: Isolate for minimum 2 weeks before introduction to resident population
• During outbreak: Isolate sick horses for 21 days after resolution of signs in last affected horse
• Temperature monitoring: Take temperatures of all horses twice daily during outbreak
• Equipment: Do not share buckets, tack, grooming tools between horses; handle infected horses last
• Personnel: Change clothes, wash hands, disinfect footwear between horses
• Disinfection: EIV is susceptible to common disinfectants; clean all surfaces and equipment